Haleon Hopes Pathbreaking Eroxon Will ‘Resonate’ With US ED Sufferers

October will see the bricks-and-mortar launch of the first FDA-approved OTC treatment for erectile dysfunction in the US by Haleon. HBW Insight catches up with the company's North America president Lisa Paley to find out what Haleon has planned for Eroxon's arrival in stores. 

• Source: Haleon

Next month Haleon plc will become the first consumer health company to launch an FDA-approved OTC treatment for erectile dysfunction.

More from United States

Some Laid Off Employees Called Back At US FDA

 

Some FDA employees who were recently laid off by the Trump Administration are being called back to work, multiple sources confirmed to the Pink Sheet.

US Proposal To Remove Phenylephrine From OTC Monograph Could Stress-Test Streamlined Process

 

Proposed administrative order likely is first to prompt opposition from OTC industry or other stakeholders potentially delaying or deferring the agency’s expectation for moving its proposal to a deemed final order effective one year after it would be published.

FDA Clears Qnovia’s NRT Inhalation IND, Commits To ‘Stimulating’ Smoking Cessation Innovation

 

Qnovia notes NRT inhalation product recently received investigational new drug clearance from FDA as agency and NIH say innovation needed smoking cessation to help improve rate of success for quitting the habit that kills around 500,000 US consumers annually.

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

More from Leadership

Over The Counter: What To Expect From The 61st AESGP Annual Meeting, With Jurate Švarcaite

 
• By 

HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.

People On The Move: Appointments At GSCF, Kenvue, Barentz

 
• By 

A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.

US FDA Survives First Day Of Return To In-Office Work, But True Test Upcoming

 

Parking and security at the FDA’s White Oak headquarters were strained from the influx of employees who had to report to work in person on 17 March.